Saneca Invests in API Manufacturing R&D

CDMO Saneca Pharma announced that it has received a EUR1.5 million grant from the Slovak Ministry of Education, Science, Research, and Sport, which will be used to drive forward new R&D initiatives for API manufacturing. The funding has enabled Saneca to strengthen its pharmaceutical development services and establish a new R&D department, with 25 employees now based at its facility in Hlohovec, Slovakia.

Saneca Pharma received the four-year grant in partnership with organic synthesis specialist, TAU-CHEM Ltd, and both companies have now embarked on complementary research projects. Saneca is investing in laboratory research for the preparation of APIs. The main focus will be on chiral molecules, sustainable development, and green chemistry. As part of this initiative, the company will look at energy-efficient production methods and the use of renewable raw materials. Using the team’s opiate development and manufacturing expertise, combined with range of technologies available on site, the CDMO will also explore abuse-resistant techniques for finished dosage forms.